Validate Non-invasive Prenatal Tests for the Detection of Chromosomal Abnormalities
- Conditions
- Validation of New Test NIPT
- Interventions
- Other: NIPT
- Registration Number
- NCT05618431
- Lead Sponsor
- CerbaXpert
- Brief Summary
This study will be conducted on pregnant patients for whom there is a suspicion of a chromosomal abnormality of the fetus. These are patients eligible for non-invasive prenatal screening as part of their usual pregnancy surveillance. This research aims to develop and validate a new method for non-invasive prenatal testing.
This prospective collection study will allow the collection of biological samples necessary for the development, testing and validation of these new tests
- Detailed Description
The main objective : of the study is the validation of non-invasive prenatal tests for the detection of chromosomal abnormalities by analyzing the fetal DNA present in maternal blood by a new generation digital PCR.
The secondary objective of this research: is to validate the reliability of the test on both populations (affected and unaffected) and its ability to detect the following anomalies: Triple X and 22q.11.2 Micro-deletion.
Type and methodology of research :
Although the only act of the research being the sampling of a maximum of 3 additional blood tubes for a maximum volume of 30 mL during a blood test as part of the care, this study is qualified as research involving the human person at risk and minimal constraints.
Provisional research calendar :
The inclusion period for subjects is 18 months, from the date of inclusion of the first patient.
The duration of the subjects' participation in this research protocol is related to the time of inclusion and the procedure of blood collection by venipuncture.
The end of participation of patients included in the study is effective as soon as the collection of the sample is completed.
Primary endpoint:
Evaluation of the non-inferiority of a new non-invasive test for the detection of chromosomal abnormalities and to determine the accuracy of fetal sex classification by the new NIPT method combined with next-generation digital PCR from acellular fetal DNA found in maternal plasma.
Secondary endpoint:
Evaluation of test performance in both populations (affected and unaffected) Evaluation of the performance of the test to detect the following anomalies: Triple X and 22q.11.2 Micro-deletion.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 1790
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description pregnant women NIPT Pregnant woman 18 and 50 years oldbetween 10 and 40 weeks of pregnancy
- Primary Outcome Measures
Name Time Method Evaluation of the non-inferiority of a new non-invasive test for the detection of chromosomal abnormalities by analyzing the fetal DNA present in maternal blood by a new generation digital PCR 18 months As part of this study, comparative analyses will be carried out:
For qualitative variables: Pearson's Chi ² test will be used unless the estimated theoretical number in a cell is less than five, in which case the Yates continuity correction or the exact Fisher test will be applied.
For quantitative variables: the t-test or an analysis of Student's variance will be performed. Otherwise, post-hoc analyses will be performed using the Student-Neuman-Keuls test. If the data is not distributed normally, nonparametric tests will be used.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
APHP
🇫🇷Paris, France